32 results on '"Sabbatini R"'
Search Results
2. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
3. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients
4. AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK BREAST CANCER
5. DETECTION OF CIRCULATING TUMOR CELLS BY RT-PCR OF MASPIN IN PATIENTS WITH HIGH RISK BREAST CANCER UNDERGOING HIGH-DOSE CHEMOTHERAPY
6. Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
7. “Corrections to Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC”
8. Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study
9. Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
10. 927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
11. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
12. Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents
13. Prognostic role of inflammatory markers in Mestatatic Renal Cell Carcinoma (mRCC): retrospective single-centre Italian experience
14. Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
15. Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)
16. 891P - Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study
17. Outcome of patients with pancreatic metastases from renal cell carcinoma: when the site matters
18. Long-term survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide in a named patient programs (NPP)
19. Effectiveness and possible molecular factors predictive of clinical outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: a multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
20. 897P - Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
21. Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience
22. Bone Metastases from Rcc are not Always Associated with a Poor Prognosis
23. 743P - Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
24. C09 - Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
25. C14 - Retrospective observational study of Vinflunine (VFL) in patients (pts) with transitional cell carcinoma of the urothelial tract (TCCU): final results of a real world population study (MOVIE-GOIRC01/2014 trial)
26. C16 - Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents
27. C07 - Prognostic role of inflammatory markers in Mestatatic Renal Cell Carcinoma (mRCC): retrospective single-centre Italian experience
28. Treatment of Patients with Metastatic Kidney Cancer During Haemodialysis with mTOR Inhibitors
29. 828P - Bone Metastases from Rcc are not Always Associated with a Poor Prognosis
30. 790P - Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience
31. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
32. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.